FDA Approves Revumenib for Relapsed, Refractory Acute Leukemia With a KMT2A Translocation

News
Article

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Data from the phase 1/2 AUGMENT-101 study (SNDX-5613-0700; NCT04065399) showed that the menin inhibitor led to a complete remission (CR) plus CR with partial hematologic recovery (CRh; CR+CRh) rate of 21.2% (95% CI, 13.8%-30.3%) with a median duration of 6.4 months (95% CI, 2.7-not estimable). In the patients who achieved a CR or CRh with revumenib (n = 22), the median time to response was 1.9 months range, 0.9-5.6).

Moreover, 14% of 83 patients who were dependent at baseline achieved independence of red blood cell (RBC) and platelet transfusions during any 56-day post-baseline period.

Regarding safety, the most common toxicities experienced by at least 20% of patients who received the drug included hemorrhage, nausea, increased phosphate levels, musculoskeletal pain, infection, increased aspartate and alanine aminotransferase levels, febrile neutropenia, increased intact parathyroid hormone, bacterial infection, diarrhea, differentiation syndrome, prolonged electrocardiogram QT, decreased phosphate, increased triglycerides, decreased potassium, reduced appetite, constipation, edema, viral infection, fatigue, and increased alkaline phosphatase.

Recent Videos
Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC in an interview with oncology nursing news
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
Elizabeth Burton in an interview with Oncology Nursing News
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.